Mechanistic Insights Into GDFMD‐Mediated Inhibition of Liver Fibrosis via miRNA‐29b‐3p Upregulation in Wilson’s Disease
Mediators of Inflammation · 2025
DOI: 10.1155/mi/2776808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediators of Inflammation, 2025. Verfasst von Peng Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Hepatolenticular Degeneration, MicroRNAs, Drugs, Chinese Herbal. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Wilson’s disease (WD) is an abnormal copper metabolism disease. GanDouFuMu decoction (GDFMD) is a traditional Chinese medicine, whicn has shown good therapeutic effects in clinical treatment of WD liver fibrosis;but its regulatory mechanism is still unclear.
Methods
The serum of WD patients before and after GDFMD treatment were collected, the four items of liver fibrosis were detected by ELISA. The hepatic stellate cell (HSC) activities were assesed via CCK8 assay. The mRNA levels were evaluated by qPCR. The protein levels were checked by western blot. The autophygosomes were observed by transmission electron microscope (TEM). The transdifferentiation ability of HSCs into myofibroblasts was evaluated with anti‐α‐SMA antibody by immunofluorescence (IF). In copper‐laden rats with WD, the autophagy levels, and fibrosis level were observed by IF.
Results
The four items of liver fibrosis levels were decreased. GDFMD could increase the HSCs cell activity. GDFMD could increase miRNA‐29b‐3p levels, which was decreased by TGF‐β1. miRNA‐29b‐3p inhibitors could reversed the suppression response of GDFMD on the the protein expression of ULK1, beclin1, LC3, α‐SMA, and Col1. GDFMD blocked the transdifferentiation of HSCs into myofibroblasts, inhibited liver fibrosis.
Conclusion
GDFMD blocked the transdifferentiation of HSCs into myofibroblasts by upregulating miRNA‐29b‐3p, and then inhibited liver fibrosis in WD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China.
- Anhui University of Chinese Medicine Key Laboratory of Xin'an Medicine of the Ministry of Education, Hefei, Anhui, China.
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, China.
ORCID-Profile: Peng Huang, Wenming Yang
Zitieren
APA
Huang, P., Huang, Y., Dong, T., Wang, H., Wang, M., Li, X., Dong, W., Yang, Y., He, W., & Yang, W. (2025). Mechanistic Insights Into GDFMD‐Mediated Inhibition of Liver Fibrosis via miRNA‐29b‐3p Upregulation in Wilson’s Disease. Mediators of Inflammation. https://doi.org/10.1155/mi/2776808
Vancouver
Huang P, Huang Y, Dong T, Wang H, Wang M, Li X, et al. Mechanistic Insights Into GDFMD‐Mediated Inhibition of Liver Fibrosis via miRNA‐29b‐3p Upregulation in Wilson’s Disease. Mediators of Inflammation. 2025. doi:10.1155/mi/2776808
BibTeX
@article{Huang2025,
author = {Huang, Peng and Huang, Yuzhe and Dong, Ting and Wang, Han and Wang, Meixia and Li, Xiang and Dong, Wei and Yang, Yulong and He, Wei and Yang, Wenming},
title = {Mechanistic Insights Into GDFMD‐Mediated Inhibition of Liver Fibrosis via miRNA‐29b‐3p Upregulation in Wilson’s Disease},
journal = {Mediators of Inflammation},
year = {2025},
doi = {10.1155/mi/2776808}
}
EUVIMED